透過您的圖書館登入
IP:18.224.0.25
  • 期刊

市售Cephradine膠囊製劑之力價調查

An Investigation on the Quality of Cephradine Capsules in Taiwan

摘要


為配合衛生署之藥政政策,維護國人用藥安全,抗生素已自藥局下架。近年來頭孢子菌素類抗生素(Cephalosporins)的大量使用已有漸取代過去常被使用的青黴素類、紅黴素類及四環素類等抗生素之趨勢。隨著細菌抗藥性的產生,頭孢子菌素類抗生素已發展至第四代,其中Cephradine係屬第一代第一線常用藥物。為了解市售Cephradine膠囊製劑之品質,本計畫於民國90年4月至90年6月委託台北市政府衛生局、高雄市政府衛生局及全省各縣市衛生局到各公私立醫院或藥局抽取Cephradine膠囊製劑之檢體100件,共收到77件,包括國產品74件及輸入品3件。依據美國藥典第二十四版(The United States Pharmacopeia 24,2000)所記載之高效液相層析法(HPLC method)予以檢驗,不合格者再以微生物法(Bioassay)予以複驗,結果77件中有一件國產品不符合藥典規定力價之合格範圍(90~120%),合格率為98.7%。檢體外包裝標示之檢查,有一件國產品未能符合相關藥事法之規定。相關不合格檢體,均已分別函請原送驗衛生單位查明處辦中。本調查係本局之比較檢驗,曾於九十一年一月八日發布新聞在案。

並列摘要


In order to assess the quality of cephradine capsules, seventy- seven samples (74 domestic, 3 imported) were randomly collected by local health authorities in Taiwan from April to June 2001. The 77 samples were analyzed by the high performance liquid chromatographic method (HPLC) as described in the United States Pharmacopoeia (USP 24, 2000). The result showed that one out of 74 domestic products failed to meet the potency requirement (90-120 %). The other one of the domestic products did not meet the labelling requirement. The 3 imported samples were all qualified.

並列關鍵字

Antibiotics Cephradine Potency HPLC

延伸閱讀